Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · Real-Time Price · USD
4.240
-0.110 (-2.53%)
At close: Oct 29, 2026, 4:00 PM EDT
4.070
-0.170 (-4.02%)
After-hours: Oct 29, 2026, 7:59 PM EDT
Recursion Pharmaceuticals Employees
Recursion Pharmaceuticals had 600 employees as of December 31, 2025. The number of employees decreased by 200 or 25.00% compared to the previous year. That makes Recursion Pharmaceuticals the 18,701st largest employer in the world and 2,548th in the United States.
Employees
600
Change (1Y)
-200
Growth (1Y)
-25.00%
Revenue / Employee
$91,427
Profits / Employee
-$864,807
Market Cap
2.53B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 600 | -200 | -25.00% |
| Dec 31, 2024 | 800 | 300 | 60.00% |
| Sep 30, 2024 | 500 | -50 | -9.09% |
| Jun 30, 2024 | 500 | -50 | -9.09% |
| Mar 31, 2024 | 500 | 0 | - |
| Dec 31, 2023 | 500 | 0 | - |
| Sep 30, 2023 | 550 | 50 | 10.00% |
| Jun 30, 2023 | 550 | 100 | 22.22% |
| Mar 31, 2023 | 500 | 50 | 11.11% |
| Dec 31, 2022 | 500 | 100 | 25.00% |
| Sep 30, 2022 | 500 | 170 | 51.52% |
| Jun 30, 2022 | 450 | 180 | 66.67% |
| Mar 31, 2022 | 450 | 232 | 106.42% |
| Dec 31, 2021 | 400 | 69 | 20.85% |
| Sep 30, 2021 | 330 | -1 | -0.30% |
| Jun 30, 2021 | 270 | - | - |
| Mar 31, 2021 | 218 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,784 |
| ADMA Biologics | 647 |
| Arcus Biosciences | 601 |
| Biohaven | 274 |
| Viridian Therapeutics | 252 |
| Celldex Therapeutics | 198 |
| Precigen | 160 |
| Pharvaris | 148 |
RXRX News
- 3 days ago - Recursion to Host Webinar Focused on Updated REC-4881 (FAP) Data from CGA-IGC on Tuesday, November 3 - GlobeNewsWire
- 13 days ago - Recursion Pharmaceuticals price target raised to $5.90 from $5.30 at Morgan Stanley - TheFly
- 14 days ago - Cathie Wood’s ARK Investment buys 4.2M shares of Recursion Pharmaceuticals today - TheFly
- 14 days ago - Recursion Pharmaceuticals Stock (RXRX) Soars 15% on a $10M Milestone Payment from Sanofi - TipRanks
- 14 days ago - Recursion Pharmaceuticals rises 15.4% - TheFly
- 14 days ago - Recursion Pharmaceuticals reports early data from REC-1245 trial - TheFly
- 14 days ago - Recursion Pharmaceuticals provides update on REC-4881 data - TheFly
- 14 days ago - Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration - GlobeNewsWire